Loading…
Evogene Ltd. is projected to decline to $0.5104 by 2027, a 0% move from its current price of $0.512. EVGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.4867 | $0.5115 | $0.5375 | -0.11% |
| Jul 14 | $0.4763 | $0.5109 | $0.548 | -0.21% |
| Jul 15 | $0.4684 | $0.5104 | $0.5562 | -0.32% |
| Jul 16 | $0.4617 | $0.5098 | $0.563 | -0.42% |
| Jul 17 | $0.4558 | $0.5093 | $0.569 | -0.53% |
| Jul 18 | $0.4506 | $0.5088 | $0.5745 | -0.63% |
| Jul 19 | $0.4457 | $0.5082 | $0.5795 | -0.74% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4457 | $0.5082 | $0.5795 | -0.74% |
| Week 2 | $0.419 | $0.5045 | $0.6074 | -1.47% |
| Week 3 | $0.399 | $0.5008 | $0.6286 | -2.19% |
| Week 4 | $0.3823 | $0.4971 | $0.6463 | -2.91% |
| Week 5 | $0.3679 | $0.4934 | $0.6617 | -3.63% |
| Week 6 | $0.3551 | $0.4898 | $0.6755 | -4.34% |
| Week 7 | $0.3436 | $0.4862 | $0.688 | -5.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Evogene Ltd. is a computational biology company operating across Israel, the United States, Europe, and Africa. It conducts activities through three segments: Agriculture, Human Health, and Industrial Applications, and engages in seed traits and ag-chemicals work as part of its agricultural efforts.
The company also designs novel small molecules for drug development using ChemPass AI, a computational generative AI engine, and focuses on the development and commercialization of castor bean seeds for industrial uses, alongside medical cannabis products.
Evogene collaborates internationally, including a partnership with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel, reflecting its broad geographic footprint and research orientation.
Evogene Ltd. (EVGN) is categorized in Healthcare and trades with a current price of $0.50 and a market cap of $6.05M, ranking 5274. These figures place it among smaller-cap names within its sector.
The current price is assessed against a year-by-year forecast that provides min, avg, and max values along with ROI metrics. For 2026 the average is $0.50, with a range that includes a minimum of $0.39 and a maximum of $0.6082. The forecast continues through 2029 and into 2050, showing a mix of neutral, bear, and bull sentiment across years.
Key long-term forecast milestones include an average price of $0.4274 in 2030, rising to a 2033 average of $0.6008 and culminating in a 2040 average of $0.7647 and a 2050 average of $0.9301, with corresponding ROI figures that range from negative in earlier years to meaningful gains in later years.
A major floor 59.0% below — a decisive break under it would weaken the trend.
The nearest floor, 23.8% below — buyers have tended to step in here.
The nearest ceiling, 40.6% above — a clean break opens room to run.
A major ceiling 81.6% above — clearing it would confirm fresh momentum.
Key EVGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EVGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.456 | Buy | $0.4696 | Buy |
| MA 10 | $0.441 | Buy | $0.4625 | Buy |
| MA 20 | $0.482 | Buy | $0.4907 | Buy |
| MA 50 | $0.6166 | Sell | $0.5902 | Sell |
| MA 100 | $0.7203 | Sell | $0.7097 | Sell |
| MA 200 | $0.9266 | Sell | $0.9253 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.92 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 32.18 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 4.08 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -1.52 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 60.19 | Neutral |
| Momentum (10) | 0.11 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 0.47 | Buy |
| ADX (14) | 37.09 | Sell |
| ATR (14) | 0.02 | Info |
The near-term picture is neutral, with RSI at 50. The stock’s 50-day simple moving average sits at $0.6222, while the 200-day simple moving average stands at $0.9299. A near-term support level is listed at $0.39 and a nearby resistance at $0.72.
Over the last 30 days, the price traded within a range of $0.3576 to $0.6992, illustrating a relatively tight band around the current level. The combination of neutral sentiment and a modest RSI supports a cautious stance in the immediate term, with price movement likely to test the defined support and resistance margins.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.39 | $0.512 | $0.6205 | 0% | Neutral | |
| $0.3755 | $0.5104 | $0.7486 | 0% | Neutral | |
| $0.2994 | $0.4302 | $0.6701 | -16% | Bearish | |
| $0.2395 | $0.3608 | $0.5885 | -30% | Bearish | |
| $0.2788 | $0.4384 | $0.7429 | -14% | Neutral | |
| $0.2879 | $0.471 | $0.8249 | -8% | Neutral | |
| $0.3262 | $0.5542 | $0.9993 | +8% | Neutral | |
| $0.3482 | $0.6135 | $1.14 | +20% | Neutral | |
| $0.3063 | $0.559 | $1.06 | +9% | Neutral | |
| $0.2938 | $0.5547 | $1.07 | +8% | Neutral | |
| $0.3552 | $0.7893 | $1.67 | +54% | Bullish | |
| $0.4312 | $0.9582 | $2.20 | +87% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.39 | $0.512 | $0.6077 | +0.00% |
| August 2026 | $0.3844 | $0.4638 | $0.5816 | -9.42% |
| September 2026 | $0.3804 | $0.465 | $0.5947 | +0.27% |
| October 2026 | $0.3915 | $0.4841 | $0.6292 | +4.09% |
| November 2026 | $0.3789 | $0.473 | $0.6231 | -2.29% |
| December 2026 | $0.3693 | $0.4652 | $0.6205 | -1.65% |
Click any year to see its month-by-month EVGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EVGN to range from $0.39 to $0.6205 through 2026. The $0.512 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The EVGN price prediction for 2027 points to an average of $0.5104 (low $0.3755, high $0.7486) — a potential decline of 0% on today's $0.512. Price action looks broadly range-bound.
In 2028, EVGN is projected to trade between $0.2994 and $0.6701, averaging $0.4302 — a potential decline of -16% from today's $0.512. That is -16% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
Evogene Ltd.'s 2029 outlook centres on $0.3608, within a $0.2395 to $0.5885 range. That is -16% versus the projected 2028 average. That marks a -30% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2030, EVGN could reach as high as $0.7429, with a base case around $0.4384 and support toward $0.2788 — roughly -14% from $0.512. A consolidation phase looks the most probable path here.
Expect EVGN to range from $0.2879 to $0.8249 through 2031. The $0.471 average target implies a -8% move from current prices. That is up +7% on the projected 2030 average. Price action looks broadly range-bound.
The EVGN price prediction for 2032 points to an average of $0.5542 (low $0.3262, high $0.9993) — a potential gain of +8% on today's $0.512. A consolidation phase looks the most probable path here.
In 2033, EVGN is projected to trade between $0.3482 and $1.14, averaging $0.6135 — a potential gain of +20% from today's $0.512. That is up +11% on the projected 2032 average. Price action looks broadly range-bound.
Evogene Ltd.'s 2034 outlook centres on $0.559, within a $0.3063 to $1.06 range. That is -9% versus the projected 2033 average. That marks a +9% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, EVGN could reach as high as $1.07, with a base case around $0.5547 and support toward $0.2938 — roughly +8% from $0.512. Price action looks broadly range-bound.
Expect EVGN to range from $0.3552 to $1.67 through 2040. The $0.7893 average target implies a +54% move from current prices. That is up +42% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The EVGN price prediction for 2050 points to an average of $0.9582 (low $0.4312, high $2.20) — a potential gain of +87% on today's $0.512. Momentum favours further upside here.
Investing $1,000 in EVGN today (≈ 1,953.125 EVGN) could be worth
$1,871.52
+$871.52 (+87%) by 2050 · US Dollar
Based on the average projected EVGN price of $0.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EVGNwould be worth at today's price.
$1,000 invested in EVGN on Jul 10, 2025 (≈ 689.65515 EVGN) would be worth
$353.1
-$646.9 (-64.7%) today · 0.35× · US Dollar
Based on a EVGN entry price of $1.45 vs. today's $0.512.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.43 | $1,190.7 | +19.1% |
| 1 month ago | $0.59 | $867.8 | -13.2% |
| 3 months ago | $0.81 | $632.1 | -36.8% |
| 6 months ago | $1.08 | $474.07 | -52.6% |
| 1 year ago | $1.45 | $353.1 | -64.7% |
| All time (5.0y) ago | $30.4 | $16.84 | -98.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EVGN forecast.
$1.00 is within our bullish range by 2033, but above the base case.
Implied market cap at $1.00: $12.1M
The multi-year forecast presents a nuanced path for EVGN. In 2026 the average price is $0.50 with neutral sentiment, and by 2027 the average slides to $0.4986 with a small negative ROI of -0.3%. The years 2028 and 2029 show bearish sentiment and declines, with averages of $0.4159 and $0.3489 and ROI values of -16.8% and -30.2%, respectively.
In 2030 the average is $0.4274 with a negative ROI of -14.5% and neutral sentiment, followed by 2031’s average of $0.4562 and -8.8% ROI. The 2032 forecast turns modestly positive with an 8% ROI and an average of $0.5401, then 2033 moves higher to an average of $0.6008 with a 20.2% ROI and bullish sentiment. 2034 and 2035 remain neutral with smaller gains at 8.4% and 7.8% ROI, respectively.
Longer horizons show stronger upside: 2040 carries a bullish sentiment with an average of $0.7647 and a 52.9% ROI, and 2050 strengthens to a bullish stance with an average of $0.9301 and an 86% ROI. This pattern suggests meaningful long-term upside despite near-term volatility, though these are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $0.4274 with a minimum of $0.2693 and a maximum of $0.7302, and a ROI of -14.5% with neutral sentiment.
The forecast presents a mix of neutral, bearish, and bullish years. Near term (2026) shows an average around $0.50, with longer-term years such as 2030–2035 showing modest to strong upside and several bearish years in 2028–2029, indicating high variability and risk.
Forecasts show possible tops above $1 in some years, with a max of $1.12 in 2033 and higher later (e.g., $1.64 in 2040 and $2.14 in 2050). However, these are not guarantees.
The 30-day range is $0.3576 to $0.6992. The current price is $0.50, RSI 14 is 50, the 50-day SMA is $0.6222, and the 200-day SMA is $0.9299. Support is at $0.39 and resistance at $0.72.
Current price is $0.50 with a market cap of $6.05M and a rank of 5274. The asset is categorized in Healthcare.
Evogene Ltd. Community Discussion
0Share your Evogene Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.